UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Blood, 2014-06, Vol.123 (25), p.3951-3962

2014

Link zum Volltext

Verfügbarkeit prüfen

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis

Clinical chemistry (Baltimore, Md.), 2018-03, Vol.64 (3), p.547-555

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience

Haematologica (Roma), 2011-02, Vol.96 (2), p.231-237

2011

Link zum Volltext

Verfügbarkeit prüfen

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

Haematologica (Roma), 2018-05, Vol.103 (5), p.799

2018

Link zum Volltext

Verfügbarkeit prüfen

Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia

Haematologica (Roma), 2012-02, Vol.97 (2), p.246-250

2012

Link zum Volltext

Verfügbarkeit prüfen

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

Journal of leukocyte biology, 2014-01, Vol.95 (1), p.95-104

2014

Link zum Volltext

Verfügbarkeit prüfen

CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

Haematologica (Roma), 2012-02, Vol.97 (2), p.219-226

2012

Link zum Volltext

Verfügbarkeit prüfen

Rituximab for the treatment of acquired antibodies to factor VIII

Haematologica (Roma), 2007-01, Vol.92 (1), p.66-71

2007

Link zum Volltext

Verfügbarkeit prüfen

Influenza vaccination perception and coverage among patients with malignant disease

Vaccine, 2015-03, Vol.33 (14), p.1682-1687

2015

Link zum Volltext

Verfügbarkeit prüfen

Severe Life-Threatening or Disabling Anaphylaxis in Patients with Systemic Mastocytosis: A Single-Center Experience

International archives of allergy and immunology, 2012-03, Vol.157 (4), p.399-405

2012

Link zum Volltext

Verfügbarkeit prüfen

International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

The Lancet. Haematology, 2019-12, Vol.6 (12), p.e638-e649

2019

Link zum Volltext

Verfügbarkeit prüfen

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post‐induction consolidation therapy

American journal of hematology, 2016-12, Vol.91 (12), p.1239-1245

2016

Link zum Volltext

Verfügbarkeit prüfen

Genome wide molecular analysis of minimally differentiated acute myeloid leukemia

Haematologica (Roma), 2009-11, Vol.94 (11), p.1546-1554

2009

Link zum Volltext

Verfügbarkeit prüfen

Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years

American journal of hematology, 2017-10, Vol.92 (10), p.E567-E574

2017

Link zum Volltext

Verfügbarkeit prüfen

Proposed score for survival of patients with myelodysplastic syndromes

European journal of clinical investigation, 2013-11, Vol.43 (11), p.1120-1128

2013

Link zum Volltext

Verfügbarkeit prüfen

Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration

Genes chromosomes & cancer, 2008-04, Vol.47 (4), p.288-298

2008

Link zum Volltext

Verfügbarkeit prüfen

Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis

British journal of haematology, 2001-05, Vol.113 (2), p.357-364

2001

Link zum Volltext

Verfügbarkeit prüfen

Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes

Journal of geriatric oncology, 2014-07, Vol.5 (3), p.299-306

2014

Link zum Volltext

Verfügbarkeit prüfen

Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia

Blood, 2001-10, Vol.98 (7), p.2200-2209

2001

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML

European journal of internal medicine, 2009-12, Vol.20 (8), p.775-778

2009

Link zum Volltext

Verfügbarkeit prüfen

A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: Intermediate dose cytarabine (2 × 1 g/m2 on days 1, 3, and 5)

Clinical cancer research, 2004-06, Vol.10 (12), p.3965-3971

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

ThemaOncology

ThemaAged, 80 And Over

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Aged
(33)
Humans
(33)
Middle Aged
(33)
Female
(30)
Male
(30)
Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Adult
(26)
Hematology
(19)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Adolescent
(12)
Prognosis
(12)
Young Adult
(11)
Hematologic And Hematopoietic Diseases
(10)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(9)
Leukemia, Myeloid, Acute - Genetics
(7)
Leukemia, Myeloid, Acute - Drug Therapy
(6)
Mutation
(6)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Rituximab for the treatment of acquired antibodies to factor VIII

Influenza vaccination perception and coverage among patients with malignant disease

Severe Life-Threatening or Disabling Anaphylaxis in Patients with Systemic Mastocytosis: A Single-Center Experience

International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post‐induction consolidation therapy

Genome wide molecular analysis of minimally differentiated acute myeloid leukemia

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years

Proposed score for survival of patients with myelodysplastic syndromes

Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration

Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis

Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes

Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia

Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML

A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: Intermediate dose cytarabine (2 × 1 g/m2 on days 1, 3, and 5)

Aktive Filter

Suchergebnisse filtern